Incannex Healthcare Inc.

CHIA:IHL Stock Report

Market Cap: AU$98.8m

This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Incannex Healthcare Past Earnings Performance

Past criteria checks 0/6

Incannex Healthcare's earnings have been declining at an average annual rate of -43.7%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 5.7% per year.

Key information

-43.7%

Earnings growth rate

-13.5%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate5.7%
Return on equity-23.7%
Net Margin-1,970.6%
Last Earnings Update30 Jun 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Incannex Healthcare makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:IHL Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 231-2099
31 Mar 231-1998
31 Dec 221-1897
30 Sep 221-1786
30 Jun 221-1575
31 Mar 221-1465
31 Dec 211-1365
30 Sep 211-1265
30 Jun 212-1165
31 Dec 202-634
30 Sep 201-523
30 Jun 201-422
31 Dec 190-211
30 Sep 190-211
30 Jun 190-111
31 Mar 191-330
31 Dec 181-340
30 Sep 181-330
30 Jun 181-330
31 Mar 181-330
31 Dec 171-330
30 Sep 170-1230
30 Jun 170-2120
31 Mar 170-2020
31 Dec 160-1920
30 Sep 160-1010
30 Jun 160-110

Quality Earnings: IHL is currently unprofitable.

Growing Profit Margin: IHL is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: IHL is unprofitable, and losses have increased over the past 5 years at a rate of 43.7% per year.

Accelerating Growth: Unable to compare IHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: IHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).


Return on Equity

High ROE: IHL has a negative Return on Equity (-23.75%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/12/05 04:16
End of Day Share Price 2023/11/17 00:00
Earnings2023/06/30
Annual Earnings2023/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Incannex Healthcare Inc. is covered by 2 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Arron AatkarEdison Investment Research
David Joseph StormsStonegate Capital Partners, Inc.